Icagen, Inc. announced that it has entered into a three-party collaboration with the Yale School of Medicine and Pfizer, Inc. to explore the potential efficacy of investigational compounds identified by Icagen and Pfizer in their existing collaboration. P Kay Wagoner, PhD, CEO of Icagen noted, “We are very pleased that Yale researchers Stephen Waxman, MD and Sulayman Dib-Hajj MD have agreed to work with us and our partner Pfizer in the study of Nav1.7 channels from inherited erythromelalgia (IEM) patients. Drs Waxman and Dib-Hajj are among the world's leading researchers in the role of sodium channels in pain. The studies we are jointly undertaking should help us better understand how modulating Nav1.7 channels in IEM patients may reduce the extreme pain experienced by these patients. This information may additionally assist our broader efforts to find novel sodium channel treatments for patients with various pain conditions.”
Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets.